Paloma Partners’s Coherus Oncology CHRS Stock Holding History

Paloma Partners’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-45,295	Closed	-$809K	–	2121
2020 Q2	$809K	Buy	+45,295	New	+$767K	0.01%	1009

Other funds holding CHRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Paloma Partners's CHRS Position: Q3 2020 in Review

Paloma Partners sold out of Coherus Oncology (CHRS) in Q3 2020, closing a stake of 45,295 shares — an estimated $809K sold.

Paloma Partners first reported a position in CHRS in Q2 2020 and held it in 1 quarter. The position peaked at $809K in Q2 2020. 201 funds tracked by Wall St. Rank hold CHRS as of Q3 2020.

Paloma Partners reported no remaining Coherus Oncology position as of Q3 2020 after selling out during the quarter.
Paloma Partners sold 45,295 Coherus Oncology shares in Q3 2020, an estimated $809K.
Paloma Partners first reported a position in Coherus Oncology in Q2 2020 and held it in 1 quarter.
Paloma Partners's Coherus Oncology position peaked at $809K in Q2 2020.
201 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2020.

Based on Paloma Partners's 13F filing for Q3 2020, filed 16 Nov 2020.